Published in Proc Natl Acad Sci U S A on April 21, 2009
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids (2010) 1.82
Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One (2014) 1.76
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Integrating zebrafish toxicology and nanoscience for safer product development. Green Chem (2013) 0.98
Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. Clin Cancer Res (2015) 0.86
Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv (2014) 0.86
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer (2012) 0.86
Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell (2011) 0.85
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Drug delivery nanoparticles in skin cancers. Biomed Res Int (2014) 0.80
Nanoparticles and nanofibers for topical drug delivery. J Control Release (2015) 0.80
Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs. Langmuir (2014) 0.78
Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology (2012) 0.78
Biodistribution of PLGA and PLGA/chitosan nanoparticles after repeat-dose oral delivery in F344 rats for 7 days. Ther Deliv (2014) 0.77
Using distance covariance for improved variable selection with application to learning genetic risk models. Stat Med (2015) 0.77
A monoclonal antibody (Mc178-Ab) targeted to the ecto-ATP synthase β-subunit-induced cell apoptosis via a mechanism involving the MAPKase and Akt pathways. Clin Exp Med (2011) 0.76
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Curr Pharm Des (2016) 0.75
Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Aβ1-42-induced oxidative stress. J Nanobiotechnology (2017) 0.75
PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug delivery. Indian J Med Res (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem (1995) 14.14
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta (1991) 4.16
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci (2008) 2.21
Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst (2007) 2.00
Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials (2001) 1.46
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res (2005) 1.11
Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog (2000) 1.10
Vascular homing peptides with cell-penetrating properties. Curr Pharm Des (2005) 1.08
Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation (2003) 0.91
Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin Cancer Res (1999) 0.87
India's R&D: reaching for the top. Science (2005) 2.08
Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis (2006) 1.19
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res (2009) 1.13
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano (2009) 0.99
Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proc Natl Acad Sci U S A (2010) 0.99
Shape effect of carbon nanovectors on angiogenesis. ACS Nano (2010) 0.94
Roles of iNOS and nNOS in sepsis-induced pulmonary apoptosis. Am J Physiol Lung Cell Mol Physiol (2003) 0.93
Ranking chemical structures for drug discovery: a new machine learning approach. J Chem Inf Model (2010) 0.91
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis (2009) 0.90
Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J (2003) 0.90
Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One (2012) 0.89
Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci U S A (2004) 0.89
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 0.88
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer (2012) 0.86
Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology (2009) 0.85
Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell (2011) 0.85
Emp is a component of the nuclear matrix of mammalian cells and undergoes dynamic rearrangements during cell division. Biochem Biophys Res Commun (2006) 0.85
New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins. Cell Mol Life Sci (2015) 0.83
Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice. Exp Parasitol (2012) 0.81
Genomic instabilities in squamous cell carcinoma of head and neck from the Indian population. Mol Carcinog (2006) 0.81
Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle (2009) 0.79
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cell Oncol (Dordr) (2013) 0.79
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res (2013) 0.78
Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology (2012) 0.78
The dynamic glycome microenvironment and stem cell differentiation into vasculature. Stem Cells Dev (2011) 0.76
Nanoparticles in cancer chemotherapy. Prog Mol Biol Transl Sci (2011) 0.76
Emerging technologies for enabling proangiogenic therapy. Nanotechnology (2011) 0.76
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med Oncol (2013) 0.76
Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology (2014) 0.76
Cancer, signal transduction and nanotechnology. Curr Drug Deliv (2011) 0.75
Evaluation of DNA degradation using flow cytometry: promising tool for postmortem interval determination. Am J Forensic Med Pathol (2015) 0.75
Proteomic and scanning electron microscopic analysis of submandibular sialoliths. Clin Oral Investig (2012) 0.75